3.4 Diagnostic Tests, Lab Biomarkers & ECG Rhythm Analysis

3.4 Diagnostic Tests, Lab Biomarkers & ECG Rhythm Analysis

[!IMPORTANT] ANCC Exam Essential: Diagnostic interpretation on the CV-BC exam tests clinical synthesis: linking laboratory biomarker kinetics to coronary reperfusion windows, recognizing confounding factors in natriuretic peptide assays, mapping 12-lead ECG ST-segment elevation patterns to specific coronary arterial anatomy, and selecting safe stress testing modalities.

Modern cardiovascular care relies on precise biomarker kinetics, electrophysiological localization, and functional imaging. The certified cardiovascular nurse must interpret laboratory assays, recognize high-risk electrocardiographic patterns, and prepare patients safely for specialized diagnostic testing.

---

Cardiac Biomarkers & Laboratory Diagnostics

1. High-Sensitivity Cardiac Troponins (hs-cTnI and hs-cTnT)

Cardiac troponins are structural proteins of the contractile apparatus of cardiac myocytes. High-sensitivity troponin assays detect circulating troponin concentrations at the 99th percentile Upper Reference Limit (URL) of a healthy reference population with an analytical coefficient of variation (CV) ≤10%.

• Kinetics:
  • Initial Rise: Detectable within 1 to 3 hours after onset of myocardial injury.
  • Peak Elevation: Peaks at 12 to 24 hours.
  • Duration: Remains elevated for 7 to 14 days due to slow intracellular release from degrading structural myofibrils.
• Diagnostic Protocols:
  • Validated rapid rule-out/rule-in protocols (0/1-hour and 0/2-hour algorithms) utilize baseline troponin concentrations combined with absolute delta changes.
  • Acute Myocardial Infarction vs. Chronic Myocardial Injury:
    • Acute Injury (AMI): Characterized by a dynamic rise and/or fall (delta change >20%) with at least one value exceeding the 99th percentile URL.
    • Chronic Myocardial Injury: Stable, chronically elevated troponin levels with minimal or no delta change (<20% variance over serial testing). Common in end-stage renal disease (ESRD), chronic heart failure, hypertensive heart disease, and amyloidosis.
• Creatine Kinase-MB (CK-MB):
  • Rises within 4 to 6 hours, peaks at 18 to 24 hours, and returns to baseline within 48 to 72 hours.
  • Clinical Utility: Troponin has largely replaced CK-MB for initial diagnosis. However, CK-MB remains uniquely useful to diagnose early recurrent myocardial reinfarction (re-infarction within 14 days), where prolonged baseline troponin elevations obscure new acute ischemic necrosis.

2. Natriuretic Peptides: BNP vs. NT-proBNP

Ventricular myocytes synthesize and release proBNP in response to increased myocardial wall tension, ventricular stretch, and volume expansion. Cleavage produces biologically active B-type Natriuretic Peptide (BNP) (half-life ~20 minutes) and the inactive metabolite N-terminal proBNP (NT-proBNP) (half-life ~60 to 120 minutes).

+--------------------------------------------------------------------------------+
|                 Natriuretic Peptide Diagnostic Reference Matrix                |
+--------------------------------------------------------------------------------+
| Marker    | Rule-Out HF  | Acute Decompensated HF Rule-In Thresholds           |
+-----------+--------------+-----------------------------------------------------+
| BNP       | <50 pg/mL    | >100 pg/mL                                          |
| NT-proBNP | <300 pg/mL   | Age <50: >450 pg/mL | Age 50-75: >900 | Age >75: >1,800 |
+--------------------------------------------------------------------------------+

• Critical Clinical Confounders:
  1. Renal Impairment (eGFR <60 mL/min): NT-proBNP is cleared almost exclusively by the kidneys; renal dysfunction causes marked accumulation and disproportionately high values. BNP is cleared by neutral endopeptidases (neprilysin) and clearance receptors as well as kidneys, making it less dramatically distorted by moderate renal failure.
  2. Severe Obesity (BMI ≥30 kg/m²): Adipose tissue expresses natriuretic peptide clearance receptors (NPR-C). Circulating BNP and NT-proBNP levels are suppressed by up to 50% in obese patients, requiring lower diagnostic cutoff thresholds.
  3. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy: Sacubitril/valsartan inhibits neprilysin, the enzyme responsible for degrading BNP. Consequently, circulating BNP levels paradoxically increase during ARNI therapy and do not reflect clinical worsening. In contrast, NT-proBNP is NOT a substrate for neprilysin; NT-proBNP levels accurately decline during effective ARNI therapy and must be used for monitoring.

3. Lipid Panel Calculations & Advanced Atherogenic Markers

• The Friedewald Formula for calculating Low-Density Lipoprotein Cholesterol (LDL-C):

$\text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \left(\frac{\text{Triglycerides}}{5}\right)$

• Critical Limitation: The Friedewald formula is mathematically invalid when serum triglycerides exceed 400 mg/dL (and loses accuracy at triglycerides >200 mg/dL), because chylomicrons and VLDL composition deviate from the assumed 5:1 ratio. In hypertriglyceridemia (>400 mg/dL), direct LDL measurement via ultracentrifugation or automated direct homogeneous assay must be ordered.
• Advanced Atherogenic Biomarkers:
  • Non-HDL Cholesterol: Calculated simply as Total Cholesterol - HDL-C. Reflects total atherogenic particle burden (LDL + VLDL + IDL + Lp(a)); target is LDL goal + 30 mg/dL.
  • Apolipoprotein B (ApoB): Measures the exact number of circulating atherogenic particles (each atherogenic lipoprotein carries exactly one ApoB-100 molecule). Highly predictive of cardiovascular events in metabolic syndrome and hypertriglyceridemia.
  • Lipoprotein(a) [Lp(a)]: An independent, genetically determined variant of LDL linked to apo(a); highly pro-atherogenic and pro-thrombotic. Levels >50 mg/dL (>125 nmol/L) confer severe lifelong cardiovascular risk.

4. Electrolytes & Coagulation Monitoring in Cardiovascular Care

• Potassium (K+): Normal 3.5–5.0 mEq/L. Cardiac Target: 4.0–5.0 mEq/L.
  • Hyperkalemia (>5.0 mEq/L): Tall peaked symmetric T waves, PR prolongation, flattening of P waves, QRS widening, sine-wave progression, and ventricular fibrillation or asystole.
  • Hypokalemia (<3.5 mEq/L): Flattened or inverted T waves, ST depression, prominent U waves following the T wave, prolonged QT interval, and heightened vulnerability to digitalis toxicity, PVCs, and polymorphic VT.
• Magnesium (Mg2+): Normal 1.7–2.2 mg/dL. Cardiac Target: ≥2.0 mg/dL.
  • Hypomagnesemia impairs the Na+/K+ ATPase pump, causing refractory hypokalemia and precipitating Torsades de Pointes (polymorphic VT). IV Magnesium Sulfate (1–2 g over 15 minutes) is the first-line treatment for Torsades.
• Sodium (Na+): Normal 135–145 mEq/L. Hyponatremia (<135 mEq/L) in heart failure indicates severe neurohormonal activation (excessive non-osmotic vasopressin/ADH release) and is an independent predictor of long-term mortality.
• Coagulation Assays:
  • Prothrombin Time (PT) / International Normalized Ratio (INR): Monitors Vitamin K Antagonists (warfarin). Therapeutic target: 2.0 to 3.0 for atrial fibrillation, DVT/PE, and bioprosthetic valves; 2.5 to 3.5 for mechanical mitral valves.
  • Activated Partial Thromboplastin Time (aPTT): Monitors Unfractionated Heparin (UFH). Therapeutic range is typically 1.5 to 2.5 times control (50–70 seconds).
  • Anti-Factor Xa Assay: The preferred laboratory gold standard for monitoring therapeutic Unfractionated Heparin (target: 0.3–0.7 IU/mL) and Low-Molecular-Weight Heparin (LMWH, enoxaparin; peak target: 0.6–1.0 IU/mL for twice-daily dosing). Anti-Xa is unaffected by acute-phase reactants, factor VIII elevations, or lupus anticoagulants.

---

12-Lead Electrocardiography: Principles & Rhythm Analysis

1. Lead Placement Protocols

• Standard Limb Leads: Lead I, II, III (bipolar); aVR, aVL, aVF (augmented unipolar).
• Precordial Leads:
  • V1: 4th intercostal space, right sternal border.
  • V2: 4th intercostal space, left sternal border.
  • V3: Midway between V2 and V4.
  • V4: 5th intercostal space, left midclavicular line.
  • V5: 5th intercostal space, left anterior axillary line (horizontal to V4).
  • V6: 5th intercostal space, left midaxillary line (horizontal to V4).
• Specialized Supplementary Leads:
  • Right-Sided Precordial Leads (V3R–V6R): Mirror image on right hemithorax. V4R (5th ICS right MCL) is the single most sensitive lead for diagnosing Right Ventricular Infarction; mandatory in all inferior STEMIs.
  • Posterior Leads (V7–V9): Horizontal plane at 5th ICS. V7 (posterior axillary line), V8 (midscapular line), V9 (left paraspinal border). Mandatory when reciprocal ST depression and tall R waves appear in V1–V3.

2. Frontal Plane Electrical Axis Determination

The mean QRS vector reflects the net direction of ventricular depolarization:

Frontal Plane Axis Quadrant Method:
- Lead I (+) and Lead aVF (+) ──> Normal Axis (-30° to +90°)
- Lead I (+) and Lead aVF (-) ──> Check Lead II:
                                   If Lead II (+): Normal Axis
                                   If Lead II (-): Left Axis Deviation (-30° to -90°)
- Lead I (-) and Lead aVF (+) ──> Right Axis Deviation (+90° to +180°)
- Lead I (-) and Lead aVF (-) ──> Extreme / Northwest Axis Deviation (-90° to 180°)

• Left Axis Deviation (LAD): Causes include Left Anterior Fascicular Block (LAFB), Left Bundle Branch Block, left ventricular hypertrophy, and prior inferior myocardial infarction.
• Right Axis Deviation (RAD): Causes include Right Ventricular Hypertrophy (RVH), acute pulmonary embolism, Left Posterior Fascicular Block (LPFB), and lateral myocardial infarction.

3. Bundle Branch Blocks (QRS Duration ≥0.12 seconds / 120 ms)

• Right Bundle Branch Block (RBBB):
  • V1–V2: Broad, notched rsR' complex ("rabbit ears").
  • I, aVL, V5–V6: Wide, slurred S wave.
  • Clinical Note: ST segments and T waves are discordant (inverted in V1–V2). Normal variant or sign of RV strain/pulmonary hypertension.
• Left Bundle Branch Block (LBBB):
  • V1–V2: Broad, deep QS or rS complex.
  • I, aVL, V5–V6: Broad, notched or slurred monophasic R wave with absent Q waves.
  • Diagnostic Dilemma: LBBB alters normal septal activation, completely obscuring classic ischemic ST elevations. Acute MI in LBBB must be evaluated using Sgarbossa Criteria (concordant ST elevation ≥1 mm in any lead; concordant ST depression ≥1 mm in V1–V3; or excessively discordant ST elevation ≥5 mm / >25% of S wave depth).

4. Coronary Arterial Territory & Infarct Localization

Diagnostic Imaging & Functional Testing Modalities

1. Echocardiography: TTE vs. TEE

• Transthoracic Echocardiogram (TTE): First-line, non-invasive ultrasound. Quantifies Left Ventricular Ejection Fraction (LVEF; normal 55–70%), regional wall motion abnormalities (hypokinesis, akinesis, dyskinesis corresponding to infarcted zones), chamber dimensions, valvular stenosis/regurgitation, and pericardial effusions.
• Transesophageal Echocardiogram (TEE): Semi-invasive ultrasound with probe positioned in esophagus directly posterior to left atrium. Delivers superior acoustic resolution.
  • Primary Indications: Detection of Left Atrial Appendage (LAA) thrombus (mandatory prior to electrical cardioversion of atrial fibrillation >48 hours duration); infective endocarditis vegetations; prosthetic valve dehiscence; thoracic aortic dissection; patent foramen ovale (PFO) bubble studies.
  • Nursing Care: Maintain NPO for 6 hours prior; obtain informed consent; monitor conscious sedation (midazolam/fentanyl); apply topical cetacaine/lidocaine pharyngeal spray; inspect teeth/dentures; assess return of gag reflex post-procedure prior to offering fluids or food.

2. Cardiac Stress Testing Modalities

3. Coronary Computed Tomography Angiography (CCTA)

• High negative predictive value (>98%) to rule out obstructive coronary artery disease in low-to-intermediate risk emergency department chest pain.
• Patient Preparation: Target resting heart rate <60 to 65 beats/min (administered oral or IV beta-blockers [metoprolol] prior to scan to minimize cardiac motion artifact); administer sublingual nitroglycerin immediately before scan to dilate coronary arteries.
• Contraindications: Severe chronic kidney disease (eGFR <30 mL/min; iodinated contrast nephropathy), severe contrast anaphylaxis, irregular rhythms (atrial fibrillation prevents prospective ECG gating).

4. Nuclear Myocardial Perfusion Imaging (SPECT / PET)

• Evaluates myocardial radiotracer uptake (Technetium-99m sestamibi/tetrofosmin) at rest versus stress.
• Reversible Defect (Ischemia): Reduced radiotracer uptake during stress that completely normalizes (re-perfuses) at rest. Indicates viable myocardium supplied by a critically stenosed coronary artery that will benefit from revascularization.
• Fixed Defect (Infarction): Absent radiotracer uptake during both stress AND rest. Represents non-viable, necrotic scarred myocardium from prior infarction.